Compare SHIP & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | RZLT |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 187.3M |
| IPO Year | 2007 | N/A |
| Metric | SHIP | RZLT |
|---|---|---|
| Price | $9.43 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $11.00 | ★ $12.33 |
| AVG Volume (30 Days) | 201.0K | ★ 14.6M |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | ★ 8.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $150,354,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $12.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.78 | $1.07 |
| 52 Week High | $11.15 | $11.46 |
| Indicator | SHIP | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 31.54 |
| Support Level | $9.22 | $1.78 |
| Resistance Level | $9.80 | $2.82 |
| Average True Range (ATR) | 0.27 | 0.49 |
| MACD | -0.14 | -0.20 |
| Stochastic Oscillator | 14.49 | 15.55 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.